Amisulpride

Description

Introducing Amisulpride Tablets by PharmAlliance International Labs Private Limited

Welcome to PharmAlliance International Labs, where mental wellness is our priority and innovation drives our pharmaceutical solutions. Our Amisulpride Tablets represent a cornerstone in psychiatric treatment, offering relief and enhancing the quality of life for individuals grappling with various mental health conditions.

Drug Classification:

Amisulpride falls within the category of atypical antipsychotics, renowned for their efficacy in managing psychiatric disorders. By antagonizing dopamine D2 and D3 receptors in the brain, Amisulpride modulates dopamine neurotransmission, alleviating symptoms associated with schizophrenia and major depressive disorder.

Formulations:

Amisulpride Tablets:

Strength: Available in multiple strengths tailored to individual patient needs.

Product Form: Oral tablets for convenient administration.

Packing Specs: Each pack contains 10 tablets.

Indications:

Amisulpride Tablets are indicated for the treatment of various psychiatric disorders, including:

Schizophrenia: Addressing both positive (hallucinations, delusions) and negative symptoms (social withdrawal, apathy) of schizophrenia.

Major Depressive Disorder (MDD): Demonstrating antidepressant properties, Amisulpride may be utilized to treat depressive episodes associated with MDD, particularly in lower doses.

Usage:

Amisulpride Tablets should be orally administered according to healthcare professional guidance. Dosage and treatment duration may vary based on the specific psychiatric condition and individual patient response. Adherence to prescribed dosage regimens is crucial for optimal therapeutic outcomes, even if symptoms improve.

Dosage:

The recommended dosage of Amisulpride varies depending on the indication and severity of the psychiatric condition:

For schizophrenia, the initial dosage typically ranges from 400mg to 800mg per day, divided into multiple doses.

In the treatment of major depressive disorder, lower doses of Amisulpride (50mg to 300mg per day) may be administered as a single daily dose.

Pharmacokinetics:

Following oral administration, Amisulpride is rapidly absorbed, with peak plasma concentrations attained within 1 to 2 hours. Extensive hepatic metabolism yields inactive metabolites, with an elimination half-life of approximately 12 hours, facilitating once or twice-daily dosing regimens.

Pharmacodynamics:

As a selective antagonist of dopamine D2 and D3 receptors, Amisulpride exerts both antipsychotic and antidepressant effects. By modulating dopamine neurotransmission, it reduces psychotic symptoms and improves mood and cognition in patients.

Side Effects:

Common side effects associated with Amisulpride treatment may include extrapyramidal symptoms (akathisia, dystonia, parkinsonism), sedation, and weight gain. Less frequently observed adverse reactions include hyperprolactinemia, orthostatic hypotension, and gastrointestinal disturbances. Rare but serious adverse events such as neuroleptic malignant syndrome (NMS) or QT prolongation may occur.

Trust in the efficacy and safety of Amisulpride Tablets from PharmAlliance International Labs Private Limited. We are committed to supporting individuals with psychiatric disorders and providing them with effective treatment options to enhance their mental health. For further information, please visit our website or consult your healthcare provider.